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Original Clinical Science—Liver
Background. About 15% of liver transplantations (LTs) in Eurotransplant are currently performed in patients with a high-
urgency (HU) status. Patients who have acute liver failure (ALF) or require an acute retransplantation can apply for this 
status. This study aims to evaluate the efficacy of this prioritization. Methods. Patients who were listed for LT with HU 
status from January 1, 2007, up to December 31, 2015, were included. Waiting list and posttransplantation outcomes 
were evaluated and compared with a reference group of patients with laboratory Model for End-Stage Liver Disease 
(MELD) score (labMELD) scores ≥40 (MELD 40+). Results. In the study period, 2299 HU patients were listed for LT. 
Ten days after listing, 72% of all HU patients were transplanted and 14% of patients deceased. Patients with HU status 
for primary ALF showed better patient survival at 3 years (69%) when compared with patients in the MELD 40+ group 
(57%). HU patients with labMELD ≥45 and patients with HU status for acute retransplantation and labMELD ≥35 have 
significantly inferior survival at 3-year follow-up of 46% and 42%, respectively. Conclusions. Current prioritization for 
patients with ALF is highly effective in preventing mortality on the waiting list. Although patients with HU status for ALF 
have good outcomes, survival is significantly inferior for patients with a high MELD score or for retransplantations. With 
the current scarcity of livers in mind, we should discuss whether potential recipients for a second or even third retrans-
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INTRODUCTION
Patients who present with acute liver failure (ALF) have 
a high risk of mortality because no bridging options are 
available for severe liver dysfunction. With the introduc-
tion of liver transplantation (LT), their chances for survival 
have increased significantly.1,2
To increase the chance of a timely, suitable donor liver, 8 
countries in Europe cooperate within Eurotransplant. This 
cooperation covers Germany, The Netherlands, Belgium, 
Austria, Croatia, Luxemburg, Hungary, and Slovenia and 
has a total population of around 136 million inhabit-
ants. Patients from these countries with primary ALF and 
patients who require an acute retransplantation (<14 days) 
can apply for a high-urgency (HU) status.3 The HU status 
gives the patient international priority within all participat-
ing countries. When a suitable organ becomes available, HU 
patients are the first to receive an offer for that organ, cross-
border.3,4 Patients can receive this status when they fulfill 
standard criteria or when accepted by an individual audit 
of 2 members of the Eurotransplant Liver and Intestine 
Advisory Committee (ELIAC) (Definitions; Methods).3
Over the last years (2012–2016), about 15% of all LTs 
within Eurotransplant were performed in patients with an 
HU status.5 HU status prioritization is currently consid-
ered justified because these patients are at imminent risk of 
death. It is primarily based on the urgency for LT, but to date, 
outcome of this allocation mode has been disregarded. The 
group of patients with HU status is heterogeneous, and there 
might be a (sub)group of patients with very poor prognosis 
even in case of an urgent LT. These HU patients are currently 
transplanted with priority over other critically ill patients 
who face the risk of dying while on the waiting list, although 
they might have a significantly higher chance of survival.
This study aims to evaluate the efficacy of the HU status 
on waiting list outcome. Then, outcome after LT is ana-
lyzed for transplanted HU patients to identify high-risk 
patients. These outcomes are compared with a reference 
group of patients without HU status but with a Model for 
End-Stage Liver Disease (MELD) score of ≥40.
METHODS
This study included anonymized data on all patients of 
16 years and older, who were listed for LT with a HU status 
within the Eurotransplant region, between January 1, 2007, 
and December 31, 2015. As a reference group, recipients most 
urgently in need for a transplantation, but without HU status, 
were included. These recipients were defined as all patients 
who reached a laboratory MELD score (labMELD) ≥40, but 
without HU status. Data were included on waiting list out-
come and, in case of a transplantation, information on donor 
and transplant characteristics. This study considered trans-
plantations instead of individual patients. Therefore, patients 
that receive multiple LTs may appear multiple times in the 
data. Follow-up data were obtained from the Eurotransplant 
Network Information System and the Eurotransplant Liver 
Follow-up Registry up to February 1, 2018. The study proto-
col was approved by the ELIAC, and no ethical statement was 
required according to European guidelines and Dutch law.
Data Analysis
The data set contained donor information on age, 
sex, latest γ-glutamyl-transpeptidase (GGT), hepatitis C 
antibodies (HCVAb) status, hepatitis B antibodies status, 
type of donation (donation after determination of circu-
latory death [DCD]/donation after brain death [DBD]), 
cause of death, body mass index (BMI), history of diabetes 
(y/n), and recipient information on age at delisting, cause 
of liver disease, BMI, HCVAb status, number of previous 
LTs, labMELD category, sex, split (y/n), allocation region 
(local, regional, extraregional), simultaneous liver and kid-
ney, rescue allocation, and total ischemic time.
Data were checked for outliers and were set at missing or 
corrected when appropriate (length/weight switch). Recipient 
BMI was missing for 1 patient, and donor last GGT was 
missing for 58 donors (0.02%). For both recipient BMI and 
donor last GGT, median values were imputed as 25.4 kg/m2 
and 32 U/L, respectively. Total ischemic time was defined as 
time between starting time of cold perfusion of the aorta in 
the donor and time of reperfusion in the recipient. In case 
of missing values (27 transplantations, 0.01%), median value 
of 8.35 hours was imputed. Donor hepatitis B antibodies, 
HCVAb, and recipient HCVAb were considered as present 
when Yes and not present when otherwise. Primary ALF 
diagnoses were categorized as Budd-Chiari, viral hepatitis, 
toxin/drug induced, Wilson’s disease, paracetamol, and other. 
Viral hepatitis comprised hepatitis A, B, C, D, E; cytomeg-
alovirus; herpes simplex virus; and other unspecified viruses. 
The category “Other” comprised causes as autoimmune dis-
eases, postoperative liver failure, (liver) trauma, anhepatic 
state, Osler’s disease, Still’s disease, Weil’s disease, pregnancy-
related illnesses, and α-1-antitrypsin deficiency. Causes for 
acute retransplantations were categorized as hepatic artery 
thrombosis (HAT), biliary tract necrosis, portal vein throm-
bosis, primary nonfunction (PNF), and other. The other cate-
gory comprised acute cellular rejections, transmitted tumor in 
a recently transplanted liver, infected biliomas, other unspeci-
fied complications of the operation, rupture of a mycotic 
aneurysm, sinusoidal obstruction syndrome, ruptured and 
bad perfused organs, risk of tumor transmission, liver necro-
sis, and compartment syndrome due to bleeding.
For all transplantations, the Eurotransplant-Donor Risk 
Index,6 simplified Recipient Risk Index,7 and Donor and 
Recipient Model7 were calculated.
Definitions
HU and MELD 40+ Groups
The HU group consisted of patients suffering from primary 
ALF who fulfilled either King’s College8 or Clichy-Villejuif9 
criteria and patients who required an acute retransplantation 
for a primary graft nonfunction or HAT3 (<14 days after 
LT) and patients not fulfilling standard HU criteria (eg, acute 
Wilson’s disease, Budd-Chiari syndrome with severe liver 
failure, life-threatening liver trauma, anhepatic state sec-
ondary to ALF with toxic liver syndrome, or patients who 
require an acute re-LT due to HAT >14 days posttransplan-
tation) but were assigned HU status based on an individual 
audit. This audit is performed by at least 2 independent liver 
transplant surgeons and/or hepatologists being members of 
the ELIAC. The MELD 40+ group consisted of patients with 
a labMELD score ≥40 on the waiting list.
Outcome Measures
Outcome after registration on the waiting list was 
defined as still on the waiting list, transplanted, deceased/
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unfit for transplantation (mortality), or removed because 
of recovery or for other reasons (psychological prob-
lems). Outcome after transplantation was analyzed for 
patient survival. Patient survival was defined as the time 
period between transplantation and death of the recipient. 
Outcome was analyzed for patients who were transplanted 
within the follow-up period of this study (February 2018).
Statistical Analysis
Waiting List Outcome
Waiting list outcome was analyzed with a compet-
ing risk analysis for all patients who received HU status 
and all patients who reached a labMELD of 40 from the 
moment of either HU listing or reaching labMELD 40. All 
HU patients were considered as 1 group for this analy-
sis because the HU status priority on the waiting list does 
not distinguish between patients with primary ALF and 
patients who require an acute retransplantation.
Posttransplantation Outcome
Patient survival at 3-year follow-up was analyzed for 
HU patients who were transplanted with a liver from a 
deceased donor (DBD or DCD type III) and compared 
with a homogenous reference group, including MELD 40+ 
patients receiving the first liver transplant from a deceased 
donor (DBD or DCD type III). This analysis was done sep-
arately for patients receiving HU status for primary ALF 
and for acute retransplantation.
Risk factors associated with patient survival at 3-year 
follow-up in HU patients were analyzed in a multivariable 
Cox regression analysis (backward selection). This was 
also done separately for (1) patients with HU status for 
primary ALF and for (2) patients with HU status for an 
acute retransplantation. On the basis of the distinct dif-
ference in outcome, patients with HU status for an acute 
retransplantation were stratified for the number of previ-
ous LTs. Then, outcome was analyzed separately for these 
groups by labMELD score category (<15, 15–24, 25–34, 
35–44, ≥45). Last, outcome was analyzed by cause of liver 
disease for patients who received HU status for primary 
ALF and for patients who received HU status for an acute 
retransplantation after 1 previous LT.
Variables were summarized by median values and inter-
quartile ranges for continuous variables and by number 
and percentages (N/%) for categorical ones. Median val-
ues were compared with a Kruskal-Wallis tests, and cat-
egorical variables were compared with Chi-square testing. 
Kaplan-Meier curves were analyzed by log-rank testing. 
A P = 0.05 was considered as statistically significant. 
Statistical analyses were performed with SPSS version 24 
and R version 3.3.2.
RESULTS
Waiting List
In the study period, 22 752 patients were registered on 
the liver waiting list. Of these patients, 2299 received an HU 
status during listing (10%) (Figure 1). They had a median 
age of 49 years old, and 48% were male. About half of 
these patients registered on the waiting list (47%) had a 
previous LT. Other demographics are shown in Table 1.
Waiting List Outcome
At 10 and 30 days after listing, 72% and 74% of all 
HU patients were transplanted, respectively (Figure  2A, 
B). Waiting list mortality was 14% at 10 days, 15% at 
FIGURE 1. Flow diagram of patients listed for liver transplantation (LT). *Patients were included who were first time transplanted with 
a liver from a donation after brain death (DBD) and donation after determination of circulatory death (DCD) type III donor. HU, high 
urgency; MELD, Model for End-Stage Liver Disease.
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30 days, and increased up to 16% at 2-year follow-up. 
The transplantation rate for HU patients was significantly 
higher (75% versus 51%; P < 0.001), and waiting list mor-
tality was significantly lower (18% versus 48%; P < 0.001) 
when compared with patients in the MELD 40+ group (n = 
1580) (Figure 2B). When comparing not-transplanted (n = 
579, 25%) to transplanted HU patients (n = 1720, 75%), 
not-transplanted HU patients were older (51 versus 49 y 
old; P = 0.037). However, no statistically significant differ-
ences were observed in the labMELD score (32 versus 32; 
P = 0.638) or in the number of previous LTs (P = 0.264) 
(data not shown).
Outcome After Transplantation
In the study period, 1719 transplanted HU transplanta-
tions were included for the analysis. In the reference group 
of patients with a labMELD score ≥40 at listing, 694 trans-
plantations were included for the analysis. Of all HU trans-
plantations, 967 (56%) were patients with primary ALF, 
whereas 752 (44%) were patients with an HU status for an 
acute retransplantation. In these HU patients (transplanted 
for failure of a previous transplantation), 651 (38%), 84 
(5%), and 17 (0.1%) transplantations were performed in 
patients with 1, 2, or ≥3 previous LTs, respectively. Most 
frequent cause of primary ALF was toxic or idiosyncratic 
drugs (25%) followed by viral hepatitis (13%), Budd-
Chiari disease (9%), and other causes (40%). The other 
causes consisted of patients without a clear cause (21%), 
other unspecified causes (14%), postoperative failure 
(3%), liver trauma (0.8%), anhepatic state (0.7%), and 1 
patient with urea cycle disorder (0.1%). In HU retrans-
plantations, PNF (46%) was the most frequent cause for 
failure of the previous transplantation followed by an 
acute HAT (26%). The median recipient age in patients 
with 1, 2, or >3 previous LTs was 53, 48, and 34 years 
old, respectively. No difference was observed between 
the groups of transplantations with 1, 2, or ≥3 previous 
LTs in the cause of failure of the previous transplantation 
(P = 0.681). Other characteristics are shown in Table 2.
Risk Factors for Posttransplant Outcome  
in HU Patients
Multivariable analysis of risk factors for patient survival 
at 3-year follow-up was performed in patients receiving HU 
status for primary ALF and for patients receiving HU status 
for an acute retransplantation, separately (Table 3). In HU 
patients with primary ALF, the following risk factors were 
identified for poor patient survival: higher donor age, split 
liver grafts, latest donor GGT, higher recipient age, cause 
of ALF, recipient BMI, and the labMELD score. For HU 
retransplantations (n = 752), the cause of graft failure of the 
previous LT, split liver grafts (n = 17, 2%), and GGT had no 
statistical significant effect, but the number of previous LTs 
was associated with a higher risk of patient mortality.
Outcome by Number of Previous Transplantations
Major differences in patient and graft survival were 
observed when posttransplantation outcome was strati-
fied for patients receiving HU status for primary ALF and 
those transplanted for failure of a previous transplanta-
tion by the number of previous LTs (Figure 3). Patient sur-
vival at 3 years decreased from 69% for HU patients with 
primary ALF to 40% to 41% in HU patients with fail-
ure of the previous LT after ≥2 previous transplantations. 
Similar results were observed for graft survival (data not 
shown). Compared with the group of MELD 40+ patients, 
HU patients who were transplanted for primary ALF were 
observed to have a better survival at 90 days (80% versus 
76%; P = 0.086), 1 year (73% versus 63%; P < 0.001), 
and 3 years (69% versus 57%; P < 0.001).
The Effect of LabMELD Score on Outcome  
in HU Patients
LabMELD score as continuous variable was strongly 
associated with outcome in HU patients (Figure S1, SDC, 
http://links.lww.com/TP/B662). The effect on 3-year 
patient survival was nonlinear in patients receiving HU 
status for primary ALF; it shows a stable risk up to a score 
of about 40 after which it increases linearly at least up to 
a labMELD score of 55 (Figure S1a, SDC, http://links.lww.
com/TP/B662). The nonlinear association of a continuous 
labMELD score in this group may be caused by differences 
in the cause of ALF within the labMELD score categories; 
some of the causes might not result in a high labMELD 
score. A relatively higher incidence of Budd-Chiari disease 
TABLE 1. 
Demographics of patients listed in HU status (n = 2299)
Recipient factor n (%)/Median (25th–75th percentile)
Age at listing 49 (36–58)
Height, cm 171 (165–178)
Weight, kg 75 (65–86)
BMI 25 (22–28)
Lab-MELD at delisting 32 (24–38)
Sex (male) 1101 (48)
Lab MELD at delisting  
 <15 201 (9)
 15–24 410 (18)
 25–34 815 (36)
 35–45 672 (29)
 ≥45 162 (39)
 Missing 39 (2)
No. of previous liver transplants  
 0 1220 (53)
 1 935 (41)
 2 122 (5)
 3 22 (1)
HCVAb (yes) 153 (7)
sRRI 1.97 (1.56–2.62)
Waiting list outcome (10 days)  
 Transplanted 72%
 Deceased while on the waiting list 14%
 Still on the waiting list 10%
 Removed (unfit, recovered, other) 4%
Waiting list outcome (30 days)  
 Transplanted 74%
 Deceased while on the waitlist 15%
 Still on the waiting list 5%
 Removed (unfit, recovered, other) 6%
BMI, body mass index; HCVAb, hepatitis C antibodies; HU, high urgency; MELD, Model for End-
Stage Liver Disease; sRRI, simplified Recipient Risk Index.
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
© 2019 Wolters Kluwer de Boer et al 1185
was, for example, observed in patients with a labMELD 
score <15 (33%) and between 15 and 24 (20%) when 
compared with 7%, 4%, and 2% in patients with a lab-
MELD score of 25 to 34, 35 to 44, and ≥45, respectively. 
In HU patients who were retransplanted for failure of the 
previous LT (1 previous LT), labMELD score did show a 
linear association (Figure S1b, SDC, http://links.lww.com/
TP/B662).
Outcome by LabMELD and Number of 
Retransplantations in HU Patients
Outcome was then stratified for labMELD score and 
the number of previous LTs in a subset analysis (Figure 4). 
The combination of both variables was very effective in 
identifying subgroups with inferior outcome. It showed 
that patients receiving HU status for primary ALF with 
a labMELD score ≥45 had a survival rate of 46% at 3 
years (Figure 4A). HU patients who were retransplanted 
after failure of ≥1 previous LT(s) and who had a labMELD 
score ≥35 had a survival rate of <42% at 3 years after 
transplantation (Figure 4B–D).
Outcome of Transplanted HU Patients by Diagnosis
Significant differences in patient survival were observed 
for patients receiving HU status for primary ALF by the 
cause of the ALF (P < 0.001) (Figure 5A). Patients listed for 
Budd-Chiari, paracetamol intoxication, and Wilson’s disease 
showed a trend toward better patient survival when com-
pared with patients presenting with liver failure induced by 
toxin and/or drugs or viral infections. Although the median 
period from listing to transplantation was 2 days in all groups, 
statistically significant differences were present between the 
FIGURE 2. Waiting list outcome. A, Waiting list outcome of patients listed in high-urgency (HU) status. B, Waiting list outcome of 
patients listed with laboratory Model for End-Stage Liver Disease (MELD) score (labMELD) ≥40.
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TABLE 2.
Demographics of transplanted HU patients by number of previous liver transplantations (n = 1719)
 Primary ALF (n = 967)
Acute retransplantation after 1 
previous LT (n = 651)
Acute retransplantation after 2 
previous LTs (n = 84)
Acute retransplantation 
after ≥3 previous LTs 
(n = 17)
Recipient factor
 Age, y 45 (33–55) 53 (45–60) 48 (40–55) 34 (25–46)
 Height, cm 170 (165–178) 173 (167–180) 173 (167–180) 175 (164–182)
 Weight, kg 75 (65–85) 78 (66–80) 72 (64–85) 63 (56–74)
 BMI 25 (22–28) 26 (23–29) 24 (21–27) 22 (19–24)
 LabMELD at transplantation 34 (28–39) 29 (21–35) 31 (25–36) 34 (23–36)
 Dialysis while on the WL 149 (15) 237 (36) 43 (51) 7 (41)
 Sex (male) 372 (39) 408 (63) 49 (58) 9 (53)
 HCVAb 19 (2) 92 (14) 12 (14) 0 (0)
 Days between HU listing and 
transplantation
2 (1–3) 2 (1–3) 2 (1–3) 2 (1–4)
 Days between listing and previous 
transplantation
n/a 5 (2–12) 7 (2–14) 8 (2–16)
LabMELD category at transplantation
 <15 57 (6) 69 (11) 6 (7) 0 (0)
 15–24 97 (10) 187 (29) 15 (18) 5 (29)
 25–34 374 (39) 228 (35) 34 (41) 6 (35)
 35–44 336 (35) 145 (22) 28 (33) 6 (35)
 ≥45 92 (10) 17 (3) 1 (1) 0(0)
 Missing 11 (1) 5 (1) 0 (0) 0 (0)
Cause ALF  
 Budd-Chiari 83 (9)
 Viral hepatitis 121 (13)
 Toxic or idiosyncratic drugs 238 (25)
 Wilson’s disease 65 (7)
 Paracetamol 53 (6)
 Other 383 (40)
 Missing 24 (3)
Cause retransplantation
 Hepatic artery thrombosis  169 (26) 23 (27) 7 (41)
 Biliary tract necrosis 22 (3) 1 (1) 0 (0)
 Other 84 (13) 14 (17) 1 (6)
 Portal vein thrombosis 26 (4) 2 (2) 0 (0)
 Primary non function 299 (46) 41 (50) 8 (47)
 Missing 51 (8) 3 (4) 1 (6)
Donor factor
 Age, y 49 (38–59) 48 (35–57) 47 (28–54) 52 (37–63)
 Height, cm 170 (165–180) 170 (165–180) 170 (165–179) 170 (165–178)
 Weight, kg 72 (65–80) 72 (65–80) 71 (64–80) 73 (67–80)
 BMI 24 (23–26) 24 (22–26) 24 (22–26) 25 (22–28)
 Last GGT (U/L) 32 (17–67) 30 (17–63) 31 (19–64) 46 (17–80)
 Sex (male) 415 (43) 324 (50) 32 (38) 10 (59)
 HCVAb (pos) 2 (0) 2 (0) 0 (0) 0 (0)
 HBcAb (pos) 32 (3) 16 (3) 2 (2) 1 (6)
 Donor type (DCD) 9 (1) 5 (1) 0 (0) 1 (6)
 Split liver (yes) 30 (3) 15 (2) 0 (0) 2 (12)
Transplant factor
 Allocation     
  Local 34 (4) 32 (5) 1 (1) 0 (0)
  Regional 91 (9) 59 (9) 11 (13) 1 (6)
  Extraregional 842 (87) 560 (86) 72 (86) 16 (94)
 Rescue (yes) 9 (1) 3 (1) 2 (2) 0 (0)
 Cold ischemia time (hours) 8.37 (6.35–10.42) 7.85 (6.28–9.87) 8.02 (6.23–9.82) 7.00 (5.22–9.69)
Continued next page
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groups (<0.001). Patients with Budd-Chiari had the longest 
mean time period between listing and LT (3.4 days).
In patients with HU status for failure of the previous LT 
(1 previous LT), those with an acute HAT (n=167) show 
better patient survival when compared with patients with 
a PNF (n = 299) at 1 year (66% versus 52%; P = 0.007) 
and at 3-year follow-up (62% versus 49%; P = 0.009). 
The difference in survival at 90 days of 73% versus 66% 
was not statistically significant (P = 0.118; Figure  5B). 
When compared with PNF patients, HAT patients were 
observed to have a longer median time period between the 
previous LT to relisting (8 days [3–14 days] versus 2 days 
[1–8 days]; P < 0.001) and a trend for longer median time 
period between the relisting in HU status and retransplan-
tation (2 days [1–4] versus 2 days [1–3]; P = 0.078).
TABLE 2. (Continued)
Demographics of transplanted HU patients by number of previous liver transplantations (n = 1719)
 Primary ALF (n = 967)
Acute retransplantation after  
1 previous LT (n = 651)
Acute retransplantation after  
2 previous LTs (n = 84)
Acute retransplantation 
after ≥3 previous LTs 
(n = 17)
Risk indices
 sRRI 2.62 (2.06–3.30) 1.67 (1.47–1.97) 1.58 (1.33–1.97) 1.56 (1.26–1.84)
 ET-DRI 2.12 (1.80–2.39) 2.05 (1.74–2.34) 1.97 (1.73–2.30) 2.25 (2.02–2.68)
 DRM 4.25 (3.12–5.42) 2.73 (2.19–3.42) 2.59 (2.14–3.20) 2.46 (2.21–3.39)
ALF, acute liver failure; BMI, body mass index; DCD, donation after determination of circulatory death; DRM, Donor and Recipient Model; ET-DRI, Eurotransplant-Donor Risk Index; GGT, γ-glutamyl-
transpeptidase; HAT, hepatic artery thrombosis; HBcAb, hepatitis B antibodies; HCVAb, hepatitis C antibodies; HU, high urgency; labMELD, model for end-stage liver disease calculated based on 
laboratory values; LT, liver transplantation; PNF, primary nonfunction; sRRI, simplified Recipient Risk Index.
TABLE 3. 
Multivariable analysis of factors associated with patient survival at 3-year follow-up in HU patients
 Patients with primary ALF (n = 967)
Patients after failure of a previous LT  
(n = 752)
 HR (95% CI) P HR (95% CI) P
Donor     
 Age, y 1.010 (1.003-1.018) 0.010 1.008 (1.001-1.015) 0.033
 Split, y 2.242 (1.206-4.168) 0.011 NS NS
 Latest GGT (U/L) 1.002 (1.000-1.003) 0.015 NS NS
 BMI NS NS 1.038 (1.005-1.073) 0.025
Recipient     
 Age, y 1.028 (1.019-1.038) <0.001 1.011 (1.002-1.020) 0.017
 Cause of liver disease (Budd-Chiari)  0.009 N/A
  Viral hepatitis 1.270 (0.668-2.415) 0.466
  Toxin/drug induced 1.314 (0.726-2.378) 0.367
  Wilson’s disease 1.091 (0.509-2.338) 0.822
  Other 1.870 (1.073-3.259) 0.027
  Paracetamol 0.870 (0.379-1.993) 0.741
  BMI 1.043 (1.020-1.068) <0.001 NS NS
Transplant     
 Total ischemic time (continuous h) NS NS 1.057 (1.025-1.091) <0.001
 No. of previous LTs N/A   
  1  0.013
  2 1.474 (1.075-2.020) 0.016
  ≥3 1.877 (0.982-3.587) 0.057
 MELD category     
  <15  <0.001  <0.001
  15–25 1.068 (0.586-1.949) 0.829 1.369 (0.851-2.200) 0.195
  25–35 0.849 (0.495-1.458) 0.554 2.018 (1.282-3.177) 0.002
  35–45 0.698 (0.401-1.215) 0.204 2.494 (1.568-3.968) <0.001
  ≥45 2.045 (1.131-3.696) 0.018 1.744 (0.745-4.087) 0.200
Not significant in multivariable analysis backward selection (Wald): donor sex, HCVAb, HBcAb, cause of death donor, allocation region, total ischemic time, diabetes, days between HU and LT, donation 
after determination of circulatory death, kidney combination, rescue allocation, and recipient HCVAb.
For missing data for one of the variables, 35 of all 967 patients with primary ALF and 60 of all 752 acute retransplantations were excluded for this analysis.
ALF, acute liver failure; BMI, body mass index; CI, confidence interval; GGT, γ-glutamyl-transpeptidase; HBcAb, hepatitis B antibodies; HCVAb, hepatitis C antibodies; HR, hazard ratio; HU, high urgency; 
LT, liver transplantation; MELD, Model for End-Stage Liver Disease; N/A, not applicable; NS, not significant.
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DISCUSSION
This study shows that the current HU prioritization is 
highly effective to transplant patients with ALF or who 
require an acute retransplantation within days. However, 
because of the prioritization for HU patients, other patients 
are disadvantaged. Transplanting these high-risk patients 
therefore represents an important dilemma in which inter-
ests of individual patients compete with interests of all 
patients on the waiting list, as a group.10 This dilemma is 
even more important in a context of scarcity of transplant-
able livers and a substantial waiting list mortality in the 
Eurotransplant region.
Posttransplantation outcomes are currently not taken 
into account in the allocation algorithm for livers within 
the Eurotransplant region.4 Especially for the HU prior-
itization, current criteria focus primarily on identifying 
patients who will die without a transplantation, and there 
is no distinction by prognosis.8,9 Although results from 
this study show that the majority of patients with HU sta-
tus for primary ALF have better outcomes than MELD 40 
patients, some (substantial) groups of HU patients have 
not. Nevertheless, these HU recipients (retransplantations 
or patients with a very high MELD score) receive abso-
lute priority over other regular patients despite their infe-
rior posttransplantation survival, even when these other 
patients are in an urgent need for a transplantation (as 
reflected in a labMELD score ≥40).
On the basis of the inferior outcomes, it has been sug-
gested before to limit the maximum number of LTs.11-16 We 
feel that such absolute guidelines would not be favorable as 
the clinical evaluation of individual patients remains impor-
tant, and exceptions should still be possible. Another sug-
gestion would be to reconsider the absolute priority of all 
HU patients over non-HU recipients. Sharma et al17 stated 
in 2012 that based on the higher waiting list mortality and 
better posttransplant outcome, MELD 40+ patients should 
be assigned higher priority than patients with status-1A. 
Based on our results, this would not apply to all, because 
HU patients with primary ALF have better outcomes than 
MELD 40+ recipients. It could, however, apply to HU 
patients with primary ALF and a MELD score ≥45 and/or 
for patients with HU status for an acute retransplantation 
after ≥1 previous LTs and a MELD score ≥35 who have a 
survival rate at 3 years of 46% and 42%, respectively. It 
might therefore be justified to differentiate within the abso-
lute priority of HU status. On the basis of the (major) differ-
ences in outcome, patients with ≥2 previous LTs might, for 
example, receive only national priority (instead of interna-
tional priority) or only extra exception MELD points. But 
most important, knowledge and education about outcome 
of such patients is critical, and there is a key role for the 
treating physician and transplant center. With this knowl-
edge, a critical evaluation should be done whether such 
patients are to be relisted and subsequently receive a (scarce) 
liver over other very ill patients on the waiting list.
Significant differences in waiting list outcome are 
observed when comparing outcome for patients listed for 
emergency LT in Eurotransplant to other transplantation 
organizations; for example, when waiting list outcome of 
HU patients in Eurotransplant is compared with status-1 
or the later status 1-A in the United States.18 Kremers 
et al19 analyzed 720 patients listed in status-1 in 2004. 
Of these, 46% were listed for an acute retransplanta-
tion (47% in this study). Of all status 1 patients, 56% 
were transplanted and 13% had died 30 days after list-
ing. Sharma et al17 compared waiting list mortality after 
14 days between patients with a MELD score ≥40 with 
patients listed in status-1A status in 2012. They observed 
a patient mortality on the waiting list of 50% and 30% 
in patients with MELD ≥40 and status-1A, respectively. 
Within Eurotransplant, a higher proportion of the HU 
patients is transplanted in a shorter period of time (72% 
after 10 days), whereas waiting list mortality (15%) is 
about similar or lower. Our results are more comparable 
to patients listed with a super-urgent status in France20 and 
patients listed for emergency LT in the United Kingdom.2 
FIGURE 3. Posttransplantation outcome (patient survival) of high-urgency (HU) patients with primary acute liver failure (ALF), HU 
patients with failure of a previous liver transplantation (LT) by the number of previous transplantations and of first time transplanted Model 
for End-Stage Liver Disease (MELD) 40 patients.
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FIGURE 4. Posttransplantation outcome (patient survival) of high-urgency (HU) patients by laboratory Model for End-Stage Liver 
Disease (MELD) score category and number of retransplantations. A, HU patients with primary acute liver failure (ALF; n = 967). B, 
HU retransplantations with 1 previous liver transplantation (LT; n = 651). C, HU retransplantations with 2 previous LTs, n = 84. D, HU 
retransplantations with ≥3 previous LTs, n = 17.
A B
FIGURE 5. Posttransplantation outcome (patient survival) of high-urgency (HU) patients by cause. A, Patient survival of HU patients 
with primary acute liver failure (ALF). B, Patient survival of HU retransplantations after 1 previous transplantation by cause.
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They report a waiting list mortality of 14% and 17% 
and a transplant rate of 73% and 76% in France and the 
United Kingdom, respectively.
The observed posttransplantation outcomes for first-
time transplanted patients with ALF of 75% and 72% 
at 1 and 3 years are in accordance with other studies. In 
comparing results, it is of note that although most patients 
with primary ALF included in this study fulfill either 
King’s or Clichy-Villejuif’s criteria for ALF, many patients 
were accepted for HU status by an expert panel of the 
Eurotransplant liver committee. Although this might be 
a potential limitation for comparing outcome with other 
regions and/or databases, this is the current practice within 
the Eurotransplant region. Other studies have a reported 
patient survival that varies from 69% to 81% at 1 year 
and from 64% to 78% at 3 years’ follow-up.2,14,15,17,21-23 
Results on outcome after acute retransplantations are 
more scarce. Posttransplantation survival is reported to 
vary from 54% to 75% at 1 year and from 49% to 67% 
after 3 years.13,14,16,24,25 In these patients, the time period 
between the first and second transplantation11,24 and the 
reason for retransplantation25 are reported to have an 
important effect on outcome. Survival at 30 days after 
retransplantations was, for example, reported to be over 
90% for HAT, whereas patients with a PNF seem to do 
a lot worse with survival around 80%.19 Better outcome 
for patients with HAT when compared with PNF was also 
observed in our study. It is, however, interesting to see that 
the distribution of retransplantation indication differs 
significantly.11,14 The observation that outcome decreases 
with an increasing number of previous LTs is confirmed by 
studies from the United States and data from the European 
Liver Transplant Registry.12,14,15 It would be furthermore 
of interest to see whether livers from DCD donors may 
be used for urgent liver (re)transplantations. In this data 
set, such transplantations were scarce and limited a more 
detailed analysis.
Our results reflect the struggle between the interest of 
individual patients and all patients on the waiting lists as 
a whole. The absolute priority of the HU status is now 
applied to a heterogeneous group of patients with primary 
ALF or with failure of previous LT(s), and other patients 
are therefore disadvantaged. To achieve a fair balance 
between HU and elective patients, the granting of HU sta-
tus should be based on the actual waiting list mortality 
and the chances of success of the transplantation. Until 
that moment, HU requests should be critically evaluated 
by the community and, in times of organ scarcity, only be 
requested for patients with an acceptable prognosis when 
transplanted.
CONCLUSIONS
The prioritization for patients with ALF is highly effec-
tive in preventing mortality on the waiting list. Patients 
with HU status for primary ALF have a relatively high 
patient survival that exceeds survival of other seriously ill 
patients (eg, those with a MELD score of 40+) or patients 
who have HU status for a (acute) retransplantation. With 
the current scarcity of livers in mind, it has to be discussed 
whether recipients should still be prioritized for a second or 
even third retransplantation over other potential recipients 
who have a much better prognosis after transplantation.
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